SPOTLIGHT: Analyst lengthens timeline for Cervarix

by admin |


A Morgan Stanley analyst is raising the prospect that GlaxoSmithKline's Cervarix could be delayed five years beyond the 2009 approval expected by most analysts on Wall Street. Report

Suggested Articles

contract
Pharma

Mostly quiet till now, Merck unveils a trio of COVID-19 deals

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

by Eric Sagonowsky
Vaccines
Manufacturing

U.K. grants new vaccine manufacturing center £131M

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

by Eric Sagonowsky
AstraZeneca
Manufacturing

AstraZeneca scores $1.2B from U.S. for COVID vaccines

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.

by Eric Sagonowsky